Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

An exclusive interview with Pfizer’s Wayne Simmons on reshaping customer experience by listening to those interacting with ...

Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...

After many years of struggling to bring out important new drugs, Pfizer is now launching several potential blockbusters in cancer and immunology. The company's 2023 acquisition of Seagen has also ...